Bifrost Biosystems Appoints Industry Veteran Jonas Jarvius, PhD as CEO
July 30 2024 - 9:30AM
Business Wire
Bifrost Biosystems, a pioneer in Optical Pooled Screening (OPS)
technologies, today announced the appointment of experienced life
sciences industry executive, Jonas Jarvius, PhD, as Chief Executive
Officer, President and Director. He brings to Bifrost over 15 years
of C-level executive experience from both private and public
companies translating innovative technologies into commercial
products that impact human health outcomes.
“On behalf of our board of directors, we enthusiastically
welcome Jonas to his new role as President and CEO of Bifrost and
look forward to the many successes ahead for him and the team,”
said Shawn Marcell, co-founder and Chairman of Bifrost. “Jonas’s
strong technical background combined with his demonstrated business
acumen will bring a level of rigor and visionary leadership
essential to driving Bifrost’s success.”
Dr. Jarvius earned his doctoral degree in Molecular Medicine
from Uppsala University where his research focused on developing
Proximity Ligation and Padlock probe-based molecular recognition
technologies as well as isothermal amplification techniques.
Several of these technologies have subsequently been commercialized
in successful companies such as Olink, Q-linea, Umbrella Science,
and Sigolis (Ginolis) where Jonas is a founder or cofounder. Dr.
Jarvius most recently served as chief executive officer of Q-Linea,
a diagnostics company focused on improving sepsis treatment and
reducing antimicrobial resistance. In this role, he led the company
from an initial technology to a multinational commercial
enterprise.
“I am excited to lead Bifrost and work with such an
exceptionally talented team,” said Jonas. “In my career, I have had
the good fortune of developing and commercializing disruptive
technologies in protein interaction analysis, rapid Antibiotic
Susceptibility Testing and advanced microfluidics. The Bifrost OPS
technology is similarly well-positioned to disrupt drug discovery
and empower researchers to make better-informed decisions.”
Bifrost's advanced OPS platform revolutionizes functional
genomics through high-speed, microscopy-based pooled single-cell
screens of CRISPR-based perturbations. The resulting extensive
dataset facilitates understanding of complex biological processes,
target identification and validation – actionable insights that
accelerate discovery pipelines in biological research.
About Bifrost Biosystems
Bifrost is a life sciences tools company offering
high-throughput single-cell optical pooled screening and analysis
solutions that deliver insights into functional cell biology and
drug discovery. The lead OPS platform is well-aligned with the
trending needs of drug discovery research for speed, scale, and
quality understanding of biology within budget. Learn more at
www.bifrost.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730452961/en/
For inquiries and further information, please contact: Jackie
Lemaitre, VP of Corporate Development, Bifrost Biosystems Email:
pr@bifrost.bio